C.J. Packard

2.7k total citations
58 papers, 2.2k citations indexed

About

C.J. Packard is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Cancer Research. According to data from OpenAlex, C.J. Packard has authored 58 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Surgery, 24 papers in Endocrinology, Diabetes and Metabolism and 22 papers in Cancer Research. Recurrent topics in C.J. Packard's work include Lipoproteins and Cardiovascular Health (28 papers), Cancer, Lipids, and Metabolism (20 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (20 papers). C.J. Packard is often cited by papers focused on Lipoproteins and Cardiovascular Health (28 papers), Cancer, Lipids, and Metabolism (20 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (20 papers). C.J. Packard collaborates with scholars based in United Kingdom, Finland and United States. C.J. Packard's co-authors include J. Shepherd, A R Lorimer, Marja‐Riitta Taskinen, Howard R. Slater, Alison F. Munro, A M Gotto, Muriel Caslake, Naveed Sattar, I. A. Greer and Colin Berry and has published in prestigious journals such as Journal of Biological Chemistry, Circulation and Journal of Clinical Investigation.

In The Last Decade

C.J. Packard

57 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C.J. Packard United Kingdom 21 999 925 395 370 369 58 2.2k
Barry Gumbiner United States 25 1.1k 1.1× 1.3k 1.4× 266 0.7× 356 1.0× 597 1.6× 51 2.7k
Josephine Cooney United Kingdom 13 280 0.3× 471 0.5× 207 0.5× 226 0.6× 232 0.6× 17 1.5k
Bernhard Föger Austria 22 750 0.8× 784 0.8× 356 0.9× 202 0.5× 377 1.0× 52 1.6k
Marit S. Nenseter Norway 28 303 0.3× 676 0.7× 223 0.6× 203 0.5× 346 0.9× 57 2.0k
Anders Gustafson Sweden 21 671 0.7× 485 0.5× 256 0.6× 222 0.6× 305 0.8× 48 1.7k
Dorothy Bedford United Kingdom 22 1.2k 1.2× 875 0.9× 594 1.5× 318 0.9× 342 0.9× 35 2.0k
Melissa A. Austin United States 10 1.2k 1.2× 984 1.1× 432 1.1× 302 0.8× 191 0.5× 10 1.9k
John W. Gaubatz United States 27 710 0.7× 1.5k 1.6× 450 1.1× 658 1.8× 529 1.4× 42 2.7k
Antonio J. Vallejo‐Vaz Spain 19 469 0.5× 877 0.9× 369 0.9× 282 0.8× 123 0.3× 51 1.5k
E. Windler Germany 25 1.3k 1.3× 1.2k 1.3× 569 1.4× 614 1.7× 807 2.2× 82 3.1k

Countries citing papers authored by C.J. Packard

Since Specialization
Citations

This map shows the geographic impact of C.J. Packard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C.J. Packard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C.J. Packard more than expected).

Fields of papers citing papers by C.J. Packard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C.J. Packard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C.J. Packard. The network helps show where C.J. Packard may publish in the future.

Co-authorship network of co-authors of C.J. Packard

This figure shows the co-authorship network connecting the top 25 collaborators of C.J. Packard. A scholar is included among the top collaborators of C.J. Packard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C.J. Packard. C.J. Packard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Packard, C.J., Marja‐Riitta Taskinen, Elias Björnson, et al.. (2025). Genetically determined increase in apolipoprotein C-III (APOC3 gain-of-function) delays very low-density lipoprotein clearance in humans. Atherosclerosis. 404. 119166–119166. 3 indexed citations
2.
Ehrenborg, Ewa, et al.. (2002). The microsomal triglyceride transfer protein-493T allele confers increased risk of coronary heart disease. Circulation. 106. 746–746. 46 indexed citations
3.
Norrie, John, A. Gaw, Jane B. Ford, et al.. (2002). C-reactive protein is an independent predictor of risk for the development of diabetes mellitus in the West of Scotland Coronary Prevention Study. 22(5). 12 indexed citations
4.
Ng, PC, et al.. (2001). Deceptive hyperbilirubinaemia in a newborn with familial lipoprotein lipase deficiency. Journal of Paediatrics and Child Health. 37(3). 314–316. 5 indexed citations
5.
Packard, C.J., John Norrie, Ian Ford, Stuart M. Cobbe, & Jonathan Shepherd. (1997). 1.P.153 Influence of pravatatin and plasma lipids on clinical events, in the West of Scotland Coronary Prevention Study (WOSCOPS). Atherosclerosis. 134(1-2). 49–49. 1 indexed citations
6.
Caslake, Muriel, A. Gaw, J. Hinnie, et al.. (1995). The effect of pharmacological agents on low density lipoprotein subfractions. Atherosclerosis. 115. S27–S27. 1 indexed citations
7.
Packard, C.J., et al.. (1993). A Pilot Scheme for Improving the Accuracy of Serum Cholesterol Measurement in Scotland and Northern Ireland. Annals of Clinical Biochemistry International Journal of Laboratory Medicine. 30(4). 387–393. 11 indexed citations
8.
Tait, Graeme W., et al.. (1992). Probucol reduces plasma lipid peroxides in man. Atherosclerosis. 97(1). 63–66. 13 indexed citations
9.
Warwick, Graham, C.J. Packard, Jennifer Stewart, et al.. (1992). Post‐prandial lipoprotein metabolism in nephrotic syndrome. European Journal of Clinical Investigation. 22(12). 813–820. 11 indexed citations
10.
Taskinen, Marja‐Riitta, C.J. Packard, & J. Shepherd. (1990). Effect of Insulin Therapy on Metabolic Fate of Apolipoprotein B–Containing Lipoproteins in NIDDM. Diabetes. 39(9). 1017–1027. 92 indexed citations
11.
Packard, C.J. & J. Shepherd. (1990). Cholesterol, lipoproteins and atherosclerosis. vmr-1(1). 91–98. 2 indexed citations
12.
Series, J.J., E.M. Biggart, D S O’Reilly, C.J. Packard, & J. Shepherd. (1988). Thyroid dysfunction and hypercholesterolaemia in the general population of Glasgow, Scotland. Clinica Chimica Acta. 172(2-3). 217–221. 48 indexed citations
13.
Demant, Thomas, Richard S. Houlston, Muriel Caslake, et al.. (1988). Catabolic rate of low density lipoprotein is influenced by variation in the apolipoprotein B gene.. Journal of Clinical Investigation. 82(3). 797–802. 62 indexed citations
14.
Shepherd, J., et al.. (1988). Very low density lipoprotein apolipoprotein B metabolism in humans. Journal of Molecular Medicine. 66(16). 703–712. 15 indexed citations
15.
Kerr, David, et al.. (1988). Comparative cellular uptake and cytotoxicity of a complex of daunomycin-low density lipoprotein in human squamous lung tumour cell monolayers. Biochemical Pharmacology. 37(20). 3981–3986. 6 indexed citations
16.
Shepherd, J. & C.J. Packard. (1986). Receptor-independent low-density lipoprotein catabolism. Methods in enzymology on CD-ROM/Methods in enzymology. 129. 566–590. 13 indexed citations
17.
Shepherd, J., Muriel Caslake, A R Lorimer, B D Vallance, & C.J. Packard. (1985). Fenofibrate reduces low density lipoprotein catabolism in hypertriglyceridemic subjects.. Arteriosclerosis An Official Journal of the American Heart Association Inc. 5(2). 162–168. 81 indexed citations
18.
Atmeh, Ragheb F., et al.. (1983). The hypolipidemic action of probucol: a study of its effects on high and low density lipoproteins.. Journal of Lipid Research. 24(5). 588–595. 61 indexed citations
19.
Shepherd, J., et al.. (1979). Receptor-mediated low density lipoprotein catabolism in man.. Journal of Lipid Research. 20(8). 999–1006. 143 indexed citations
20.
Shepherd, J., et al.. (1977). Effect of saturated vs poly unsaturated fat on high density lipo protein metabolism in normal subjects. Clinical research. 25(3). 499. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Barry Gumbiner Breakdown of academic impact, for papers by Josephine Cooney Breakdown of academic impact, for papers by Bernhard Föger Breakdown of academic impact, for papers by Marit S. Nenseter Breakdown of academic impact, for papers by Anders Gustafson Breakdown of academic impact, for papers by Dorothy Bedford Breakdown of academic impact, for papers by Melissa A. Austin Breakdown of academic impact, for papers by John W. Gaubatz Breakdown of academic impact, for papers by Antonio J. Vallejo‐Vaz Breakdown of academic impact, for papers by E. Windler
Rankless by CCL
2026